hydroxide ion

Subscribe to Selected New Research on hydroxide ion

5189 relevant articles (228 outcomes, 689 trials/studies) found for this Bio-Agent

Also Known As:

OH-; hydroxide; hydroxyl ion

Relationship Network

Bio-Agent Context: Research Results

Inorganic Chemicals: 6

Experts

1.	Su, M-C: 3 articles (08/2007 - 03/2005)
2.	Michael, J V: 3 articles (08/2007 - 03/2005)
3.	Srinivasan, N K: 3 articles (08/2007 - 03/2005)
4.	Geisser, Peter: 3 articles (01/2007 - 01/2007)
5.	Potgieter, Maria A: 3 articles (01/2007 - 01/2007)
6.	Venter, Cornea: 3 articles (01/2007 - 01/2007)
7.	Venter, Jan L: 3 articles (01/2007 - 01/2007)
8.	Potgieter, Johannes H: 2 articles (01/2007 - 01/2007)
9.	Knerer, Birgit: 2 articles (09/2006 - 01/2004)
10.	Formanek, Michael: 2 articles (09/2006 - 01/2004)

Related Diseases

1.	Neoplasms (Cancer) 09/01/2009 - "Most respondents felt managers treated referral to occupational health (OH) differently for employees with cancer compared with management referral for employees with other diagnoses, with 45% of respondents indicating referral may take place too late to be effective in securing a return to work. " 01/01/1981 - "OH-BBN administration schedule had a significant effect on cancer incidence: administration of a total dose of 30, 20, or 15 mg OH-BBN in 20 weekly fractions was more effective in cancer induction than was the same total dose given in 5 fractions. " 08/01/2009 - "Gd@C(82)(OH)(22) nanoparticles are more effective in inhibiting tumor growth in mice than some clinical anticancer drugs but have negligible side effects. " 12/23/1994 - "Although [3H]OCT administered intravenously into FA-6 tumor-bearing nude mice was cleared from the circulation more rapidly than [3H]1,25-(OH)2D3, the uptake of [3H]OCT into the tumor tissue, relative to the radioactivity in the circulation, was greater than that of [3H]1,25-(OH)2D3. " 02/01/2007 - "Some compounds of Cephalostatin family have shown anti-cancer activity against human cancer cell line and active intensity has close with the stereochemistry of the substituted group, for example, beta-OH at C-12 in compound 2 showed less promising results and the mixture 3 (alpha + beta) showed a large enhancement of the activity compared to the compound 2. So, the work was concentrated on the synthesis diastereomers 10 and 11 were obtained in a pure form." Order ALL the reference details at left...
2.	Secondary Hyperparathyroidism 07/01/1994 - "The aim of this double blind, comparative, randomized study was to eveluate the efficacy of treatment with 1-alpha-OHD3 plus 24,25(OH)2D3 in patients with secondary hyperparathyroidism.A group of 46 patients, 26 females and 20 males, aged 19-67, on chronic haemodialysis, was examined. " 12/01/1993 - "Conflicting results have been reported regarding the efficacy of intermittent versus continuous administration of 1,25(OH)2D3 in renal secondary hyperparathyroidism. " 10/01/1989 - "It is concluded that 3 g/day CaCO3 is equivalent to 2 g/day Al(OH)3 in terms of its phosphate-binding effect, and the prescription of CaCO3 together with 1 alpha (OH)D3 ameliorates secondary hyperparathyroidism." 11/01/2008 - "The main purpose of the present studies was to increase the knowledge of the action and effects of different treatment regimes with 1alpha(OH)D3, and thereby to improve the prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. " 07/01/2004 - "The aim of the study was to investigate the influence of 1,25(OH)2D3 therapy on long-term control of glycemia in hemodialyzed (HD) patients with severe secondary hyperparathyroidism (SHP). " Order ALL the reference details at left...
3.	Psoriasis (Pustulosis Palmaris et Plantaris) 02/01/1990 - "1,24R(OH)2D3 may be useful in the treatment of psoriasis." 10/01/2007 - "CONCLUSION: UVB therapy in elderly psoriatic women improved psoriasis, increased serum 25(OH)D3 synthesis and reduced serum PTH concentrations." 12/01/1986 - "Controlled trials of large numbers of patients with psoriasis vulgaris treated with 1 alpha(OH)D3 are under way." 02/01/2003 - "1,25(OH)(2)D and its analogs have been developed for treating the hyperproliferative disease psoriasis. " 06/01/2001 - "1 alpha,25-Dihydroxyvitamin D(3) (1 alpha,25(OH(2))D(3)) and its analogs are used to treat psoriasis because of their potent antiproliferative activity. " Order ALL the reference details at left...
4.	Prostatic Neoplasms (Prostate Cancer) 03/01/2005 - "Although not entirely consistent, some studies suggest that higher circulating 1,25(OH)2D may be more important than 25(OH)D for protection against aggressive, poorly-differentiated prostate cancer. " 03/01/2001 - "We provide preliminary evidence that 1alpha,25(OH)(2)D(3) may be effective in slowing the rate of PSA rise in selected cases of prostate cancer. " 02/10/2009 - "This study aims to investigate whether serum levels of 25(OH)D are associated with prognosis in patients with prostate cancer. " 04/01/2007 - "In most studies, 1,25(OH)2D plasma level was not found to be reduced in patients with prostate cancer. " 03/01/2007 - "Despite intriguing results from laboratory studies, previous epidemiological studies showed inconsistent associations of circulating levels of 25(OH)D, 1,25(OH)2D, and several VDR polymorphisms with prostate cancer risk. " Order ALL the reference details at left...
5.	Osteoporosis 12/01/2004 - "The levels of OC, BAP, CTx, PTH and 1,25(OH)2D were significantly greater for women with osteoporosis than for those without. " 11/20/1989 - "From the above, it was suggested that 1,25(OH)2D3 might be effective for the treatment of senile osteoporosis especially at the dose of 0.5 microgram/day." 04/01/2009 - "A threshold in the positive relationship between 25(OH)D and different BMD parameters was visible at a 25(OH)D level of 50 nM. Our study showed a high prevalence of low 25(OH)D in postmenopausal women with osteoporosis worldwide. " 11/01/2007 - "The aim of the present study was to evaluate serum 25(OH)D and its relationship with nutrient intakes in postmenopausal Brazilian women with osteoporosis. " 01/01/2002 - "Enrolled in the present study were 16 elderly osteoporosis women aged 72.6 +/- 4.5 years to whom 1 microgram of 1 alpha(OH)D3 was administered daily. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Vitamin D
2.	Calcitriol (Calcijex)
3.	Cholecalciferol (Vitamin D3)
4.	Calcium
5.	Doxorubicin (Adriamycin)
6.	Parathyroid Hormone (Parathormone)
7.	Phosphorus
8.	1-hydroxycholecalciferol (alfacalcidol)
9.	25-hydroxyvitamin D
10.	Cyclophosphamide (Cytoxan)

Related Therapies and Procedures

1.	Renal Dialysis (Hemodialysis)
2.	Drug Therapy (Chemotherapy)
3.	Aftercare (After-Treatment)
4.	Injections
5.	Heterologous Transplantation (Xenotransplantation)

Best Treatments:
Research Summary Report
on Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 20112 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>